As the national peak body for life sciences and Australian life sciences innovators, AusBiotech welcomed a large number of new members between May and June this year including: AlphaRET, Canary Regulatory Affairs, CBE Pure Solutions, Charles River Laboratories Australia, Chimeric Therapeutics, Formrite Group, MahPharma, McCullough Robertson Lawyers, Nyrada Inc, PharmAust, TekCyte, UTS Faculty of Science, Viedoc Technologies AB, and Wellumio.
AusBiotech CEO, Rebekah Cassidy said, “We couldn’t be more pleased to welcome these new members to our 3,000+ strong nation-wide community of life science companies, services, senior leaders, researchers and experts from across our industry’s value chain.”
“AusBiotech’s ongoing strength of membership means we are perfectly positioned to truly hear and understand the evolving needs of our diverse and growing industry, build connections, and provide an informed, strong representative voice to government and other stakeholders.”
“My team and I are looking forward to working with our new members to provide value and collectively build Australia’s biotechnology ecosystem.”
AusBiotech’s new members include:
- is a wholly owned subsidiary of Nova Eye Medical Limited. AlphaRET Pty Ltd is a special purpose entity established to commercialise 2RT®, a nano-pulse ophthalmic laser technology that is a breakthrough treatment for Age related Macular Degeneration (AMD).
- is a consultancy established to help bring new treatments to patients globally. Canary assists companies at all stages of product development, from the selection and project management of suppliers for raw materials and specialised GMP, GLP and GCP compliant service providers, to the preparation of study protocols and reports. Canary supports product registration by establishing an early dialogue with international regulatory authorities and through the preparation of regulatory dossiers.
- is an Australian-based contract manufacturing organisation, supporting companies in the development, translation, and commercialisation of a range of life science products through fill and finish and microbiological testing services.
- supports a wide range of microbial identification methods, endotoxin testing and Rapid microbial methods. Its Australian site offers a progressive portfolio of quality control testing solutions for the pharmaceutical, medical device, and consumer care industries to help bring products to market safely and efficiently.
- is a clinical stage cell therapy company and focused on bringing the promise of cell therapy to life for more patients with cancer. Chimeric’s team of cell therapy pioneers and experts is focused on the discovery, development, and commercialisation of the innovative and promising cell therapies. Chimeric currently has a diversified portfolio that includes two autologous CAR-T cell therapies and allogeneic NK cell therapies.
- is an NSW-based service provider that designs, manufactures, and distributes formed plastic packaging and displays, including custom designed medical packaging, for businesses across Australia.
- are experts in the storage, distribution, labelling and packing of clinical trial materials in APAC and Global regions. Its GMP is designed to meet the needs of clinical trial sponsors, contract research organizations (CROs), and other vendors involved in the clinical trial supply chain.
- is a leading independent Australian law firm with more than 350 employees located across offices in Brisbane, Sydney, and Canberra. Its life sciences team is one of the largest nationally with clients ranging from ASX-listed life sciences companies, to emerging companies, universities, and research institutes.
- (ASX:NYR) is a US registered, Australia domiciled, drug discovery and development company specialising in first-in-class, small molecule drugs to treat neurological and cardiovascular diseases. Nyrada’s two main programmes are a cholesterol-lowering drug and a drug to treat brain injury, specifically stroke and traumatic brain injury (TBI).
- is a clinical-stage biotechnology company developing new therapeutics for human and animal health applications. The company is repurposing monepantel for the treatment of cancer in dogs and neurodegenerative diseases in humans.
- was incorporated in May 2018 as a spin out of the CRC for Cell Therapy Manufacturing. It is a B2B enterprise developing novel nano-scale coatings that can improve the safety and performance of medical devices. The company’s main focus is on biofilm-resistant coatings to help reduce the incidence of infection associated with implantable devices.
- – as the University Technology of Sydney’s science faculty, UTS Faculty of Science is committed to changing the world through exceptional graduates, impactful scientific research, and innovative technology. UTS Science currently homes over 2,500 undergraduate and postgraduate students and over 340 academic, technical and professional staff members.
- provides innovative software designed to increase collaboration across the clinical trials industry by streamlining the electronic data capture (EDC) process. Since 2003, its eClinical solution has supported more than 5,000 studies by collecting data from patients and allowing it to flow smoothly and securely across sites and countries.
- is a medical technology startup developing an ultra-portable MRI scanner (Axana) with a primary focus on early diagnostic triage for acute stroke, a leading cause of human mortality and disability. Co-founded in 2019 and led by co-CEOs Dr Shieak Tzeng and Dr Sergei Obruchkov, the company’s mission is to advance the availability and affordability of point-of-care imaging. Wellumio’s second-generation scanner, Axana, achieves a 99% weight reduction compared to conventional MRI, establishing it as the most portable imaging system in the global USD15B mobile imaging services market.
Become a member of AusBiotech to strengthen your connections in the Australian life sciences industry, benefit from longstanding relationships across government, industry and academia, and shape advocacy efforts and help foster a sustainable and globally competitive sector.
